Status:
TERMINATED
Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Diabetes Mellitus
Diabetic Neuropathy, Painful
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic neuropathy. It is a selective antagonist that binds competitively to the glutamate site of the N-methyl-D-aspa...
Eligibility Criteria
Inclusion
- Women of childbearing potential must have a negative serum pregnancy test result at screening
- Diabetes mellitus (type I or II) that is controlled by oral or parenteral hypoglycemic agents or diet
- Diagnosis of painful diabetic distal symmetric sensory/motor polyneuropathy
Exclusion
- Pregnancy, lactation, or plans to become pregnant during the study
- Depo-Provera or oral contraceptives that have been taken for less than 1 month before study day 1 if not using another medically accepted form of birth control
- History of multiple drug allergies that may put the subject at greater risk during study participation in the opinion of the investigator
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00073034
Start Date
January 1 2004
End Date
December 1 2004
Last Update
February 21 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.